[
  {
    "ts": null,
    "headline": "Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced positive topline results from ICONIC-LEADa, a pivotal Phase 3 investigational study of icotrokinra (JNJ-2113), the first targeted oral peptide that selectively blocks the IL-23 receptor, in adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO). The Phase 3 study met its co-primary endpoints of Psoriasis Area and Severity Index (PASI) 90b and Investigator's Global Assessment (IGA) of 0/1c response at week 16 a",
    "url": "https://finnhub.io/api/news?id=96ac0c3ba9e953789ef6f5cd11773ff08822ac8e5c1b4db3e89c3f9318991821",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731965400,
      "headline": "Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results",
      "id": 131463203,
      "image": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced positive topline results from ICONIC-LEADa, a pivotal Phase 3 investigational study of icotrokinra (JNJ-2113), the first targeted oral peptide that selectively blocks the IL-23 receptor, in adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO). The Phase 3 study met its co-primary endpoints of Psoriasis Area and Severity Index (PASI) 90b and Investigator's Global Assessment (IGA) of 0/1c response at week 16 a",
      "url": "https://finnhub.io/api/news?id=96ac0c3ba9e953789ef6f5cd11773ff08822ac8e5c1b4db3e89c3f9318991821"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Tweedy Browne Portfolio - Q3 2024 Update",
    "summary": "Tweedy Browne's 13F portfolio value drops to $2.10B with reductions in top positions like Berkshire Hathaway and Alphabet. Read an update on the portfolio here.",
    "url": "https://finnhub.io/api/news?id=95e30e21a5ecd4ff7a3e46256e2f327f543e5f56f2078576e636f34b699dc5ee",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731962146,
      "headline": "Tracking Tweedy Browne Portfolio - Q3 2024 Update",
      "id": 131461978,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/953164652/image_953164652.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Tweedy Browne's 13F portfolio value drops to $2.10B with reductions in top positions like Berkshire Hathaway and Alphabet. Read an update on the portfolio here.",
      "url": "https://finnhub.io/api/news?id=95e30e21a5ecd4ff7a3e46256e2f327f543e5f56f2078576e636f34b699dc5ee"
    }
  },
  {
    "ts": null,
    "headline": "How Robert F. Kennedy Jr. could impact the healthcare sector as secretary of health",
    "summary": "Robert F. Kennedy Jr.'s nomination to lead HHS is causing cautious concern among investors. Here's which companies and stocks could be impacted, as well as which policies are in line for disruption.",
    "url": "https://finnhub.io/api/news?id=851cf6b4c5d4a0866123957a35947294e4255cb32265a9dc3c0f0a274885791b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731954468,
      "headline": "How Robert F. Kennedy Jr. could impact the healthcare sector as secretary of health",
      "id": 131459215,
      "image": "https://s.yimg.com/ny/api/res/1.2/1DWnyssLRzOazAJTQv5_Dw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDI-/https://s.yimg.com/os/creatr-uploaded-images/2024-10/693db1d0-a5d6-11ef-bdb5-d669618dab8f",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Robert F. Kennedy Jr.'s nomination to lead HHS is causing cautious concern among investors. Here's which companies and stocks could be impacted, as well as which policies are in line for disruption.",
      "url": "https://finnhub.io/api/news?id=851cf6b4c5d4a0866123957a35947294e4255cb32265a9dc3c0f0a274885791b"
    }
  },
  {
    "ts": null,
    "headline": "Globus Medical Stock: Re-Rated After A Solid Year",
    "summary": "Globus Medical saw strong growth from the NuVasive deal. Read why GMED stockâs $81 valuation suggests the easy gains may be over for now.",
    "url": "https://finnhub.io/api/news?id=4a1fedff1088ec0b8e16ab42575de36bf7804b587b19d07bc0c94150afe8daca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731949707,
      "headline": "Globus Medical Stock: Re-Rated After A Solid Year",
      "id": 131460687,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1860536835/image_1860536835.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Globus Medical saw strong growth from the NuVasive deal. Read why GMED stockâs $81 valuation suggests the easy gains may be over for now.",
      "url": "https://finnhub.io/api/news?id=4a1fedff1088ec0b8e16ab42575de36bf7804b587b19d07bc0c94150afe8daca"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson : to Participate in the Stifel 2024 Healthcare Conference Press Release",
    "summary": "Media contact: Investor contact: ...",
    "url": "https://finnhub.io/api/news?id=48e399c2542765e58e9b6a6fee147ea32343dedc7da7ff68665df3d3c4e0f513",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731948628,
      "headline": "Johnson & Johnson : to Participate in the Stifel 2024 Healthcare Conference Press Release",
      "id": 131460391,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Media contact: Investor contact: ...",
      "url": "https://finnhub.io/api/news?id=48e399c2542765e58e9b6a6fee147ea32343dedc7da7ff68665df3d3c4e0f513"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson stock underperforms Monday when compared to competitors despite daily gains",
    "summary": "Johnson & Johnson stock underperforms Monday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=b6cf18b9ad2b10bb424e3421c51b8382706a460bc7d9c4f4bc5c16657e09a874",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731947460,
      "headline": "Johnson & Johnson stock underperforms Monday when compared to competitors despite daily gains",
      "id": 131473228,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock underperforms Monday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=b6cf18b9ad2b10bb424e3421c51b8382706a460bc7d9c4f4bc5c16657e09a874"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson appoints CIO to lead business technology strategy",
    "summary": "Chris Della Rocca previously served the company as CIO overseeing technical operations and risk.",
    "url": "https://finnhub.io/api/news?id=64f1f77192dfaf6e24295fa2391eff0e5bd4e6b0791a1bc1c56b2699e4d9c1c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731946850,
      "headline": "Johnson & Johnson appoints CIO to lead business technology strategy",
      "id": 131463205,
      "image": "https://imgproxy.divecdn.com/bKIy4ceTn7PxeXEpUtVNe42wMaiktUyfrpu2Gq0gziA/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNzQxMzEzMzE2LmpwZw==.webp",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Chris Della Rocca previously served the company as CIO overseeing technical operations and risk.",
      "url": "https://finnhub.io/api/news?id=64f1f77192dfaf6e24295fa2391eff0e5bd4e6b0791a1bc1c56b2699e4d9c1c2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Management presents at Stifel 2024 Healthcare Conference (Transcript)",
    "summary": "Johnson &amp; Johnson (NYSE:JNJ) Stifel 2024 Healthcare Conference November 18, 2024 10:55 AM ETCompany ParticipantsMichael Bodner - Group President, Heart...",
    "url": "https://finnhub.io/api/news?id=95f9608aec57b9279f11b415882742a90cbf91d8cf002beede18fc73b6cb8f03",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731945732,
      "headline": "Johnson & Johnson (JNJ) Management presents at Stifel 2024 Healthcare Conference (Transcript)",
      "id": 131459923,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson &amp; Johnson (NYSE:JNJ) Stifel 2024 Healthcare Conference November 18, 2024 10:55 AM ETCompany ParticipantsMichael Bodner - Group President, Heart...",
      "url": "https://finnhub.io/api/news?id=95f9608aec57b9279f11b415882742a90cbf91d8cf002beede18fc73b6cb8f03"
    }
  },
  {
    "ts": null,
    "headline": "CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC",
    "summary": "The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.",
    "url": "https://finnhub.io/api/news?id=e13fa5df2d03abe62d7df944a46e245162d5a56b2f88af777ee8afe8ea04e12a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731933720,
      "headline": "CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC",
      "id": 131442359,
      "image": "https://media.zenfs.com/en/zacks.com/f3f15a36f635cd8200884e1a968d4c3d",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.",
      "url": "https://finnhub.io/api/news?id=e13fa5df2d03abe62d7df944a46e245162d5a56b2f88af777ee8afe8ea04e12a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly follows J&J in suing Biden administration over 340B rebates",
    "summary": "Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead of giving them upfront discounts on 340B drugs.",
    "url": "https://finnhub.io/api/news?id=42b6157559a639c8fb988e93cbb0e38c62ac1cde47102801ff153c74d6962abb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731925680,
      "headline": "Eli Lilly follows J&J in suing Biden administration over 340B rebates",
      "id": 131452200,
      "image": "https://imgproxy.divecdn.com/1OnmBT_xahaGMYJ4YQEtUap2qLwX0LK27MtLQ4KX8C4/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTIwOTI0NzMyMTNfZUdpWFJ1MS5qcGc=.webp",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead of giving them upfront discounts on 340B drugs.",
      "url": "https://finnhub.io/api/news?id=42b6157559a639c8fb988e93cbb0e38c62ac1cde47102801ff153c74d6962abb"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson - CHMP recommends RYBREVANT in combination with LAZCLUZE for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer",
    "summary": "BEERSE, BELGIUM - Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has...",
    "url": "https://finnhub.io/api/news?id=e7fac32880d4f83208f9ff25300d0f157e05005d55f06cfff992523dab8cc397",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731913589,
      "headline": "Johnson & Johnson - CHMP recommends RYBREVANT in combination with LAZCLUZE for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer",
      "id": 131439953,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "BEERSE, BELGIUM - Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has...",
      "url": "https://finnhub.io/api/news?id=e7fac32880d4f83208f9ff25300d0f157e05005d55f06cfff992523dab8cc397"
    }
  },
  {
    "ts": null,
    "headline": "J&J: positive CHMP opinion for Lazcluze in lung cancer",
    "summary": "Janssen-Cilag International NV, a subsidiary of Johnson & Johnson, has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing...",
    "url": "https://finnhub.io/api/news?id=77687678427db57df5f68297f1e820e097c7024dbe10d0592590e615fefcbb50",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731909318,
      "headline": "J&J: positive CHMP opinion for Lazcluze in lung cancer",
      "id": 131439144,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Janssen-Cilag International NV, a subsidiary of Johnson & Johnson, has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing...",
      "url": "https://finnhub.io/api/news?id=77687678427db57df5f68297f1e820e097c7024dbe10d0592590e615fefcbb50"
    }
  }
]